Skip to main content
  • En
  • Français

Top Navigation

  • Newsroom
  • Contact Us

Main navigation

  • About Us
  • Products
  • Technology
  • Clinical Studies
  • Investors
  • News
  • En
  • Français

Press Releases

Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion

  • Read more about Bone Therapeutics’ allogeneic cell therapy product, ALLOB, shows 90% fusion rate at 24 months in Phase IIa study in lumbar spinal fusion

Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa

  • Read more about Bone Therapeutics to present at 2020 Virtual Cell & Gene Meeting on the Mesa

Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia

  • Read more about Bone Therapeutics, Link Health and Pregene to develop and commercialize the ALLOB allogeneic bone cell therapy platform in China and Southeast Asia

Information on the total number of voting rights and shares

  • Read more about Information on the total number of voting rights and shares

Bone Therapeutics reports half year 2020 results

  • Read more about Bone Therapeutics reports half year 2020 results

Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region

  • Read more about Bone Therapeutics announces expansion of its pipeline supported by funding from the Walloon Region

Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study

  • Read more about Bone Therapeutics receives EUR 1.0 million to advance ongoing JTA-004 phase III knee osteoarthritis study

Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020

  • Read more about Bone Therapeutics announces Annual General Meeting results and confirms outlook for 2020

Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 8 February 2021

  • Read more about Bone Therapeutics: Notice of Extraordinary Shareholders’ Meeting on 8 February 2021

Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

  • Read more about Bone Therapeutics treats first patient in ALLOB Phase IIb tibial fracture study

Pagination

  • Previous page ‹‹
  • Next page ››
Subscribe to Press Releases
Wallonie Eu Flag

BioSenic SA
Rue Granbonpré 11 – Bâtiment H (bte 24)
1435 Mont-St-Guibert – Belgium
T.: +32 493 09 73 66
info@biosenic.com
Contact

Sign upfor our press releases

Receive information about BioSenic

Sign Up

Footer menu

  • Privacy Policy
  • Trademarks Copyrights
  • Users conditions